Topic:

M&A

Latest Headlines

Latest Headlines

St. Jude shells out $200M for chronic pain therapy manufacturer NeuroTherm

St. Jude Medical signed on the dotted line to acquire interventional pain management therapy manufacturer NeuroTherm for approximately $200 million in cash, strengthening its foothold in the chronic pain market.

Abbott continues evolution toward devices, planning to sell generics portfolio for $5.3B

Following the $5.3 billion sale of Abbott Laboratories' developed market generic drugs business to Mylan, diagnostics and devices will account for the majority of the company's sales, while pharmaceuticals' contribution to company-wide sales will stand at about 15%, based on 2013 earnings.  

Riled by $84,000 Sovaldi, Senate panel digs into Gilead's Pharmasset buy

Add a new set of pricing foes for Gilead Sciences). A U.S. Senate committee has joined the forces arrayed against the company's breakthrough hepatitis C drug Sovaldi and its $84,000 price tag.

Shire finally comes to AbbVie's buyout table, thanks to $53B-plus bid

Look who's talking. After four takeover bids from AbbVie, target Shire is finally in discussions with the Illinois drugmaker. And those have yielded yet another improved offer--a $53.7 billion bid Shire says its board would back.

Shire and AbbVie inch closer to a deal after weekend getaway

There's a whiff of inevitability with AbbVie's quest for Shire, as the latter company has confirmed that the two have found an agreeable price, setting the stage for a potential merger worth about $53.7 billion.

Mylan beefs up outside the U.S. with $5.3B deal for Abbott drug business

Mylan has been hunting for a buy. Now, it's found one. The Pittsburgh-based generics specialist is buying a big chunk of Abbott Laboratories' drug business, in a stock swap worth $5.3 billion. With $2 billion in annual sales, the products would jack up Mylan's top line by almost 30%.

AbbVie urges shareholders to push Shire toward deal talks

With time running out for AbbVie to strike a deal with Shire before it will have to walk away for as long as 6 months under U.K. takeover law, the Illinois-based company is encouraging top Shire shareholders to push the Irish drugmaker toward the bargaining table.

AbbVie mounts a whisper campaign to get Shire on board with its $51.5B offer

Shire has refused to negotiate with a dogged AbbVie after four increasingly priced overtures, and now, with a $51.5 billion offer on the table, AbbVie is pressing shareholders to badger the company into agreeing to a sit-down.

If Allergan has a pickup to make, make it now, shareholders say

Allergan has said it's working on some plans of its own to give investors "most of what they want" instead of the $53 billion hostile bid that Valeant and lead Allergan shareholder Pershing Square have put before them. And if those plans include a pickup of its own, it better get to it, shareholders say.

Wall Street wonders what Shire is worth

The share prices of AbbVie and takeover target Shire keep drifting downward amid sustained uncertainty over a deal. A couple of healthcare investors we talked to feel the deal is by no means definite--a concern that is also reflected in the continued wide spread between the latest offer price and Shire's share price.